Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2/3 3Phase 2 2Phase NA 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 46NIH 10NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Plasma cell 1

Conditions

Recurrence 1Multiple Myeloma 1Lung Neoplasms 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × auricularum × Clear all
NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

SWOG Cancer Research Network

Phase 2 Completed
143 enrolled 14 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡